ArticleBMJ public health2026
Human papillomavirus vaccine uptake and the impact of school-based health services in Switzerland: a cross-sectional study.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human papillomavirus (HPV) is a major cause of cervical cancer and other related diseases. Switzerland has implemented a national HPV immunisation strategy since 2007. This study examined trends in HPV vaccination coverage and valid schedule completion among adolescents in Switzerland between 2008 and 2022 and assessed differences in vaccination outcomes by delivery through school health services. Methods: We analysed data from the Swiss National Vaccination Coverage Survey, including 46 914 sampled adolescents, of whom 32 554 provided vaccination documentation. The analysis included 16-year-old girls (2008-2022) and 16-year-old boys (2017-2022). Vaccination uptake (≥1, ≥2 and ≥3 doses) and valid schedule completion (valid two-dose, valid three-dose and valid total) were estimated using weighted proportions with 95% CIs. Differences between cantons with and without HPV vaccination delivered through school health services were assessed for the 2017-2019 survey period. Multivariable logistic regression was used to evaluate factors associated with valid total schedule completion among girls (2011-2019). Results: Vaccination coverage among 16-year-old girls increased from 28.8% (95% CI 24.4% to 33.2%) in the survey period 2008-2010 to 74.6% (95% CI 72.2% to 77%) in the survey period 2020-2022 for ≥1 dose. Valid schedule completion rose substantially, particularly for the two-dose regimen after the 2012 recommendation change. Among boys, coverage reached 51.2% (95% CI 48.4% to 54%) for ≥1 dose in the survey period 2020-2022. In 2017-2019, completion of a valid HPV schedule among girls was 51.8% (95% CI 48.6% to 54.9%) in cantons with school health services versus 40.8% (95% CI 37.2% to 44.5%) in those without such services. In multivariable analyses, school health services, urban residence and French-speaking region were associated with higher odds of valid schedule completion. Conclusion: HPV vaccination coverage in Switzerland has improved over time, particularly following the introduction of the two-dose schedule. Delivery through school health services was associated with higher coverage and completion, highlighting the importance of organised vaccination delivery strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.